Home Up Feedback Contents Search Sell your Prod. Meet us News           

Home • Up





+32 1658 9045


0032 (0)16 41 44 07

+32 1650 9045


Av. de l' Armée 68

B-1040 Brussels



tel 01 43 25 01 50

fax01 43 25 01 60

9, rue Lagrange

75005 Paris


tel 02 36 00 65 93

fax 02 36 00 65 94

20135 Milano


tel +32 1658 9045

fax +32 1650 9045


Tel 058 710 33 44

Fax 00 32 16 50 90 45

ul. Grunwaldzka 88A/2

81-771 Sopot


tel +81 78 386 0860

fax +81 78 306 0296


Chuo-ku, Kobe



Canada Montreal

Česká republika Praha


Finland Helsset

Ελλάς Αθήνα

Magyarország Budapest

Ireland Dublin



Norge Oslo

Polska Warszawa

Sverige Stockholm

Schweiz Züri

US New York

Other Countries
0032 (0)16 41 44 07






Cardio MPO Reagent Kit 7601       1450 Euro
Cardio MPO Control Kit 8601          450 Euro
Cardio MPO Calibrator Kit 9601      542 Euro

Human Myeloperoxidase ELISA

CardioMPO™ ELISA based test kit for in vitro diagnostic use.  The CardioMPO™ Test measures myeloperoxidase (MPO) levels in human plasma and is intended for use as an aid in evaluating patients presenting with chest pain that are at risk for major adverse cardiac events (MACE), including myocardial infarction, need for revascularization, or death.  The CardioMPO™ test kits are currently available and testing is available through our CLIA-certified reference lab.


Heart Attack Diagnostic mpo elisa test kit has received FDA approval for a
diagnostic blood test capable of identifying
patients who are in imminent danger of heart
attack or death. The test, called CardioMPO,
measures blood levels of the enzyme
myeloperoxidase (MPO). Cleveland Clinic
researchers found that elevated MPO levels in
patients complaining of chest pain can signal
a high risk of a heart attack or cardiac death
or an acute need for intervention.

The human MPO test kit has been developed for the quantitative measurement of natural human MPO in plasma and culture medium. Myeloperoxidase (MPO) is a glycoprotein with a alpha2beta2 heteromultimer expressed in all cells of the myeloid linage. MPO is abundantly present in azurophilic granules of polymorphonuclear neutrophils. It is an important enzyme used during phagocytic lysis of engulfed foreign particles which takes part in the defense of the organism through production of hypochlorous acid (HOCl), a potent oxidant. MPO is rapidly released by activated polymorphonuclear neutrophils. Involvement of MPO has been described in numerous diseases such as atherosclerosis, lung cancer, Alzheimer's disease and multiple sclerosis. Autoimmune antibodies to MPO are involved in Wegener’s disease. Since the discovery of MPO deficiency, initially regarded as rare and restricted to patients suffering from severe infections, MPO has attracted more clinical attention.
The classical MPO assay is an enzymatic assay for activity of MPO. This classical MPO assay is hampered by the presence of inhibitory compounds in many tissue homogenates. In this type of assays spiking often gives unreliable results. Human MPO ELISA is not influenced by inhibitors of the enzyme activity due to the supplied buffer system.
The human MPO ELISA kit is intended for the quantitative measurement of the human MPO in cell culture medium and plasma. In plasma samples MPO can be measured accurately if plasma samples are diluted at least 10 times. Most reliable results are obtained if Heparin plasma is used.

CardioTACS In Situ Apoptosis Detection Kits
The CardioTACS Kit was developed to provide the heart researcher with an effective method for identifying apoptotic cells in cardiac samples. The high cellularity of cardiac tissue presents problems in permeabilization, so the CardioTACS Kit comes with two permeabilization reagents to provide options. The kit is based on DNA end-labeling using terminal deoxynucleotidyl transferase (TdT) and a modified nucleotide that is subsequently detected using our TACS Blue Label detection system. Trevigen has developed an exclusive apoptosis grade TdT enzyme that coupled with the TACS Blue Label solution provides labeling 20 to 50 times more sensitive than standard diaminobenzidine (DAB) labeling methods. To ensure ease of data interpretation when the numbers of apoptotic cells are low, CardioTACS provides Nuclear Fast Red Counterstain which provides superb contrast to the TACS Blue Label in apoptotic cells. In addition, the kit includes TACS-Nuclease that is used to generate a positive control in your own sample. The positive control provides an internal control for permeabilization and labeling so optimization is nominal and the data can be interpreted with confidence.
•   Fast. Requires less than 3 hours to complete.
•   Exclusive, non-toxic TACS Safe TdT buffer - sodium cacodylate free.
•   Unique buffer system produces more consistent labeling.
•   Performance tested on heart derived samples.
•   Exclusive Cytonin™ permeabilization reagent included.
•   TACS-Nuclease solution for preparing sample dependent positive controls included.
•   TUNEL assay
•   In situ detection of apoptosis in fixed frozen, paraffin embedded, or plastic embedded cardiac cells and tissues.
•   Assists in the identification of apoptotic morphologies.
•   Helps resolve unique problems encountered when detecting apoptotic cardiac cells.
Components: Catalog # Component Size
  4800-30-01 Proteinase K 30 µl
  4800-30-06 Strep-HRP 30 µl
  4800-30-11 TACS Blue Label™ 3 ml
  4800-30-12 Blue Strep-HRP Diluent 7.5 ml
  4800-30-14 Streptavidin-FITC 30 µl
  4800-30-15 TACS-Nuclease™ 15 µl
  4800-30-16 TACS-Nuclease Buffer 15 µl
  4800-30-17 Nuclear Fast Red 50 ml
  4810-30-02 TACS 2 TdT Labeling Buffer 100 ml
  4810-30-03 TACS 2 TdT Stop Buffer 100 ml
  4810-30-04 TACS 2 TdT dNTP 30 µl
  4810-30-05 TdT Enzyme 30 µl
  4876-05-01 Cytonin™ 5 ml
Storage: Components are stored at -20°C, 4°C, and room temperature.
References: 1. J. F. Kerr, G. C. Gobe, C. M. Winterford and B. V. Harmon (1995) Anatomical methods in cell death. Methods in Cell Biology 46, 1 - 27.
2. M. Yamawaki, A. Zurbriggen, A. Richard and M. Vandevelde (1993) Saponin treatment for in situ hybridization maintains good morphological preservation. J. Histochem. Cytochem. 41:105 - 109.
3. S.-R. Shi, R.J. Cote, L.L. Young and C.R. Taylor (1997) Antigen retrieval immunohistochemistry: practice and development. J. Histotechnology 20:145 - 154.
4. A. Migheli, A. Attanasio, W.-H. Lee, S.A. Bayer and B. Ghetti (1995) Detection of apoptosis in weaver cerebellum by electron microscopic in situ end-labeling of fragmented DNA. Neurosci. Lett. 199:53 -56.




Copyright © 2002 GENTAUR Molecular Products
Last modified: 05/29/09